Publications by authors named "Karine Almanric"
Background: Oral antineoplastic drugs (OADs) play an increasing role in the treatment of cancer. Patients must have a high degree of understanding and autonomy to manage the numerous adverse effects at home. In Quebec, recommendations have been made for oncology pharmacists to systematically counsel all patients who are starting an OAD.
View Article and Find Full Text PDFBackground: Cisplatin-induced nephrotoxicity occurs in about one-third of patients who receive this chemotherapy drug. In late 2012, the study institution began measuring serum creatinine on day 7 after administration of cisplatin to identify patients with acute renal failure.
Objective: To evaluate the extent of nephrotoxicity associated with cisplatin and the influence of risk factors for nephrotoxicity.
Objective: Despite the very good prognosis of endometrial cancer, a number of patients with localized disease relapse following surgery. Therefore, various adjuvant therapeutic approaches have been studied. The objective of this review is to evaluate the efficacy and safety of neoadjuvant and adjuvant therapies in patients with resectable endometrial cancer and to develop evidence-based recommendations.
View Article and Find Full Text PDFArticle Synopsis
- Enoxaparin dosage for obese patients and those with renal impairment is debated, and a study was conducted to compare anti-factor Xa activity in these groups against patients with normal weight and kidney function.
- A total of 233 patients participated, receiving either a 1.5 mg/kg once daily or a 1 mg/kg twice daily regimen of enoxaparin, with anti-Xa levels measured shortly after administration.
- The results indicated that while anti-Xa levels increased with body mass index, no dosage changes are needed for obese patients; however, patients with severe renal impairment might need dosage adjustments when taking the medication twice daily.